MTX2

Across TCGA pan-cancer cohorts, MTX2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MTX2 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MTX2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTX2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where MTX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.416	0.847	.001	19	view →
PDAC	OS	Quartile	All	0.712	0.935	.009	17	view →
LSCC	DFS	Tertile	II,III,IV	0.878	0.493	.018	14	view →
GBM	DFS	Tertile	All	0.928	0.658	.003	5	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MTX2–CCRCC (DFS)

Open the CCRCC breakdown →